What Happened?
Los Angeles, CA-based Michael Step as Chief Executive Officer
About the Company
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
About the Person
Senior biopharma executive with experience in leading teams in a range of pharmaceutical and biotechnology activities at specialty pharmaceutical companies, biotechnology companies, and larger pharmaceutical companies. Have led commercialization teams, scouted and led numerous significant transactions in M&A, licensing (in and out) and acquisitions of both technologies and products, and experienced at corporate fundraising. Have experience as a senior management executive with all areas of pharmaceutical development and commercialization areas.
Info Source
Press Release
Short Profile